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eply to Letter: Affordability of cancer care in the
nited Kingdom – Is it time to introduce user
harges?
ear Sir,
While Macmillan Cancer Support welcomes debate around how
o make the cost of cancer care in the UK more sustainable, we  are
oncerned that the introduction of user charges as discussed by
ggarwal and Sullivan would further worsen the relatively poor
utcomes people with cancer in the UK experience in comparison
o many other European countries.
Of particular concern is the evidence suggesting that user
harges could result in reduced screening uptake and adherence
o treatment, and an increased use of emergency care. Almost one
n four people with cancer are already diagnosed via an emergency
dmission [1], and those diagnosed this way are on average around
wice as likely to die within a year of diagnosis than those diag-
osed via an urgent GP referral [2]. The average cost of an A&E
ttendance is signiﬁcantly higher than that of a GP visit, while a
ingle non-elective (emergency) inpatient spell in the NHS costs on
verage around £2000 [3]. Any revenue generated from charging
eople with cancer to access the latest diagnostic tests or treat-
ents could easily be wiped out by the increased cost of emergency
are.
We are also deeply concerned that the evidence suggests user
harges would disproportionately affect older people and those
rom lower socio-economic backgrounds, as these groups already
xperience some of the poorest cancer outcomes in the UK. The UK
as a lower ﬁve-year survival rate than Eastern Europe for people
ged 75 or over who are diagnosed with lung, stomach or kidney
ancer [4]. Overall 5-year survival for almost all common cancers
s worse than the European average [5], and treatment rates vary
onsiderably depending on where in the country you live [6] and
n your age [7]. People with cancer from the most deprived areas
f England are a third less likely than those from the least deprived
reas to be alive ﬁve to ten years after diagnosis [8]. Any reform of
ancer care funding should seek to reduce these inequalities, not
xacerbate them.
Furthermore, being diagnosed with cancer already places a
igniﬁcant ﬁnancial burden on many people. Four in ﬁve peo-
le with cancer will experience average costs of £570 a month
ollowing diagnosis [9]. Sending people who are struggling to
ay their heating bills or feed their children while recover-
ng from cancer treatment an ‘invoice’ for their care would
ot only place them under further ﬁnancial pressure, it would
nsinuate that they themselves are a ﬁnancial burden on the
HS. Such an approach is likely to exacerbate the anxiety and
epression that people with cancer commonly experience, mak-
ng it harder for them to self-manage their condition and any
ssociated co-morbidities, and may  make some people more
eluctant to report signs of disease progression or recurrence
ttp://dx.doi.org/10.1016/j.jcpo.2014.09.002
213-5383/© 2014 Published by Elsevier Ltd. This is an open access article under the CC Bfor fear of facing further charges or becoming more of a ‘bur-
den’.
We would also question the assertion made by Aggarwal and
Sullivan that user charges may  be necessary because the cost of
cancer care in the UK is increasing at an ‘unprecedented’ rate.
NHS England ﬁgures show that in the last four years (2009/10 to
2012/13 inclusive), spend on cancer care has remained basically
static at between£105–107 per head of population. Over the past 10
years (2003/2004 to 2012/2013 inclusive), spend on cancer care has
increased at a similar level to spend on infectious diseases, mental
health and respiratory disorders [10].
In the run-up to the Westminster General Election in 2015,
Macmillan Cancer Support is calling on the main political par-
ties to commit to delivering cancer outcomes that match the
best in Europe. To make the cost of cancer care in the UK
more sustainable while achieving this aim, we must improve
prevention and early diagnosis and reduce emergency admis-
sions. People with cancer should be supported to stay as well
as possible during their diagnosis, treatment and recovery. We
must introduce holistic assessments and care pathways that take
into account people’s co-morbidities as well as their cancer.
We must reform the current one-size-ﬁts-all follow-up system
and shift more care into a community setting. What we must
not do is take advantage of people facing a life-threatening
illness because they are an easy target for revenue genera-
tion.
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